1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases

• DOI: 10.1016/j.annonc.2023.09.2382
• Publication Date: 2023-10-20T13:00:38Z
• Authors: M. Li; K. Mok; L.L. Chan; K.W.C. Lee; H.H.F. Loong; K.C. Lam; F. Mok; Y.M. Lau; O. Chen; J. Ng; B. Lam; A. Chen; W. Wong; T.S.K. Mok